Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy
Molecules · 2025
DOI: 10.3390/molecules30244802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Isis Wolf und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medical Center-University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cell Adhesion Molecules, Antigens, Neoplasm, Immunotherapy. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Federal Ministry of Economic Affairs and Climate Action, Federal Ministry of Research, Technology and Space.
Abstract (Originalsprache)
Background
Non-muscle invasive bladder cancer (NMIBC) has limited therapeutic options and high recurrence rates. Photoimmunotherapy (PIT) enables targeted tumor ablation using antibody-photosensitizer conjugates and light activation. We evaluated EGFR, Nectin-4, and TROP-2 as PIT targets using cysteine-modified antibodies conjugated to the photosensitizer WB692-CB2.
Methods
Antibodies derived from Cetuximab (Cmb, anti-EGFR), Enfortumab (Enf, anti-Nectin-4), and Sacituzumab (Sac, anti-TROP-2) were engineered with T120C and D265C mutations in the heavy chains for site-specific dye conjugation. Binding of the conjugates to BC cells was tested by flow cytometry and light-induced cytotoxicity of the conjugates, alone or in combination, was assessed by viability assays following irradiation.
Results
Cysteine-modified antibodies were produced as intact IgG molecules and were efficiently conjugated with WB692-CB2 without loss of antigen specificity. SacT120C/D265C-WB692-CB2 showed the highest target binding and achieved near-complete cell killing at a red-light dose of 32 J/cm2. CmbT120C/D265C-WB692-CB2 required a fourfold higher light dose for comparable efficacy, while EnfT120C/D265C-WB692-CB2 demonstrated lower potency. No cytotoxicity was observed in antigen-negative cells. Combined treatment enhanced cytotoxicity, indicating additive phototherapeutic effects.
Conclusions
Our findings suggest that PIT targeting EGFR, Nectin-4, or TROP-2 merits further preclinical development as a targeted therapeutic approach for NMIBC, including potential combinatorial or personalized strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Medical Center-University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany.
- Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
- Institute of Organic Chemistry, Albert-Ludwigs-Universität Freiburg, Albertstr. 21, 79104 Freiburg, Germany.
ORCID-Profile: Isis Wolf, Philipp Wolf
Förderung
- German Research Foundation
- Federal Ministry of Economic Affairs and Climate Action
- Federal Ministry of Research, Technology and Space
- Open Access Publication Fund of the University of Freiburg
Zitieren
APA
Wolf, I., Giess, N., Roider, C., Schultze-Seemann, S., Storz, J., Werz, D. B., Miernik, A., Gratzke, C., & Wolf, P. (2025). Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy. Molecules. https://doi.org/10.3390/molecules30244802
Vancouver
Wolf I, Giess N, Roider C, Schultze-Seemann S, Storz J, Werz DB, et al. Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy. Molecules. 2025. doi:10.3390/molecules30244802
BibTeX
@article{Wolf2025,
author = {Wolf, Isis and Giess, Nora and Roider, Céline and Schultze-Seemann, Susanne and Storz, Jonas and Werz, Daniel B and Miernik, Arkadiusz and Gratzke, Christian and Wolf, Philipp},
title = {Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30244802}
}
EUVIMED